Sionna Therapeutics (NASDAQ:SION) Trading Up 8.1% – Here’s Why

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) rose 8.1% during mid-day trading on Wednesday . The stock traded as high as $39.89 and last traded at $39.78. Approximately 80,230 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 298,882 shares. The stock had previously closed at $36.81.

Analysts Set New Price Targets

Several brokerages have weighed in on SION. Royal Bank Of Canada reiterated an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research note on Monday, December 1st. BTIG Research reaffirmed a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a report on Wednesday. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Lifesci Capital assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 price objective for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.43.

Sionna Therapeutics Price Performance

The company’s 50 day moving average is $40.76 and its 200 day moving average is $30.71. The stock has a market cap of $1.74 billion and a price-to-earnings ratio of -8.01.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 33,356 shares of Sionna Therapeutics stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the sale, the director directly owned 3,561,655 shares of the company’s stock, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc sold 33,356 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the transaction, the director directly owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. This represents a 0.93% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 1,071,548 shares of company stock worth $42,687,226 over the last quarter. Company insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Sionna Therapeutics in the fourth quarter valued at $440,000. Millennium Management LLC lifted its stake in shares of Sionna Therapeutics by 1,425.5% in the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock valued at $6,296,000 after purchasing an additional 200,051 shares in the last quarter. Jain Global LLC purchased a new stake in shares of Sionna Therapeutics during the 3rd quarter worth about $250,000. Bank of America Corp DE increased its position in Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after purchasing an additional 529 shares in the last quarter. Finally, Longaeva Partners L.P. purchased a new position in Sionna Therapeutics in the third quarter valued at approximately $1,807,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.